Cell & Gene: The Podcast

Nov 21 2024 91 ep. 25 mins 78

Cell & Gene: The Podcast artwork

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Copy RSS

Subscribe on Podcast Addict

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

Nov 21 2024 21 mins

We love to hear from our listeners. Send us a message.Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on site during 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies,

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

Nov 07 2024 20 mins

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Te

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

Oct 24 2024 25 mins

We love to hear from our listeners. Send us a message.This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflamm

Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

Oct 10 2024 14 mins

We love to hear from our listeners. Send us a message.Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoant

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

Sep 25 2024 22 mins

We love to hear from our listeners. Send us a message.Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa.Subscribe to the podcast!Apple | Spotify | YouTube

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

Sep 12 2024 28 mins

We love to hear from our listeners. Send us a message.Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Wr

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

Aug 29 2024 25 mins

We love to hear from our listeners. Send us a message.Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is manag

CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

Aug 15 2024 27 mins

We love to hear from our listeners. Send us a message.Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also provides a regulatory outlook for

Identifying Drug Development Opportunities for DMD with CureDuchenne

Aug 01 2024 29 mins

We love to hear from our listeners. Send us a message.Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dys

Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington

Jul 18 2024 21 mins

We love to hear from our listeners. Send us a message.Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss why in vivo delivery continues to